Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) was upgraded by analysts at Robert W. Baird from a "neutral" rating to an "outperform" rating. They now have a $11.00 price target on the stock, up previously from $3.00.
MediumReport
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) was upgraded by analysts at Robert W. Baird from a "neutral" rating to an "outperform" rating. They now have a $11.00 price target on the stock, up previously from $3.00.
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) was upgraded by analysts at Bank of America Co. from a "neutral" rating to a "buy" rating. They now have a $10.00 price target on the stock, up previously from $4.20.
LowReport
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) was upgraded by analysts at Bank of America Co. from a "neutral" rating to a "buy" rating. They now have a $10.00 price target on the stock, up previously from $4.20.
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) was given a new $4.00 price target on by analysts at Leerink Partners. They now have a "market perform" rating on the stock.
MediumReport
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) was given a new $4.00 price target on by analysts at Leerink Partners. They now have a "market perform" rating on the stock.
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: